Endothelial activation markers in anemic non-dialysis chronic kidney disease patients
- PMID: 18974656
- PMCID: PMC2818376
- DOI: 10.1159/000167872
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients
Abstract
Background/aims: Anemia in chronic kidney disease is an independent predictor of cardiovascular disease (CVD). We explored the relationship between anemia and markers of inflammation and endothelial activation in non-dialysis chronic kidney disease (ND-CKD) patients to understand this mechanism.
Methods: Cross-sectional analysis was performed on 30 adult ND-CKD patients for markers of inflammation and endothelial activation using a multiplexed immunoassay. Data were analyzed according to the anemic status defined by the modified World Health Organization criteria.
Results: Seventeen patients were classified as anemic. Baseline characteristics by anemic status were similar except that anemic patients were older (p = 0.006), had lower estimated glomerular filtration rate (eGFR; p = 0.01) and higher prevalence of CVD (p = 0.02). Compared to non-anemic patients, log-transformed values of fibrinogen (p = 0.012); von Willebrand factor (vWF, p = 0.008), vascular cell adhesion molecule-1 (VCAM-1, p = 0.025) and C-reactive protein (p = 0.043) were elevated in anemic patients. Serum ferritin (p = 0.93) and serum albumin (p = 0.06) were not different. Age and eGFR-adjusted logistic regression analysis showed that anemic patients had increased odds for a composite of higher median values of fibrinogen, vWF and VCAM-1 (p = 0.01, odds ratio 8.1, 95% CI 1.08-111.0).
Conclusion: We report the association of anemia with elevated markers of endothelial activation in ND-CKD patients. Longitudinal studies are needed to confirm our findings.
(c) 2008 S. Karger AG, Basel.
Conflict of interest statement
Dr. Singh reports receiving consulting fees from Ortho Biotech Clinical Affairs/Johnson & Johnson, Amgen, Roche, Merck, Abbott, Watson, and lecture fees from Ortho Biotech Clinical Affairs/Johnson & Johnson, Roche, Amgen, Abbott, Watson, and Genzyme; serving on advisory boards for Ortho Biotech Clinical Affairs, Roche, Watson, AMAG Inc., and Amgen, and receiving grant support from Ortho Biotech Clinical Affairs, Dialysis Clinic Inc., Roche, Baxter, Johnson & Johnson, Amgen, and Watson. Dr. Singh is a Medical Director of Dialysis Clinics Inc.
Similar articles
-
Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.Nephrol Dial Transplant. 2012 Mar;27(3):1076-83. doi: 10.1093/ndt/gfr431. Epub 2011 Jul 28. Nephrol Dial Transplant. 2012. PMID: 21799206
-
Anemia, inflammation and health-related quality of life in chronic kidney disease patients.Clin Nephrol. 2011 Jun;75(6):524-33. doi: 10.5414/cnp75524. Clin Nephrol. 2011. PMID: 21612756
-
Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.Adv Med Sci. 2008;53(1):32-6. doi: 10.2478/v10039-008-0024-x. Adv Med Sci. 2008. PMID: 18635422
-
Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3 - 5 chronic kidney disease.Clin Nephrol. 2009 Jul;72(1):21-30. doi: 10.5414/cnp72021. Clin Nephrol. 2009. PMID: 19640384 Clinical Trial.
-
Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly.J Am Med Dir Assoc. 2006 Nov;7(9 Suppl):S7-S12; quiz S17-21. doi: 10.1016/j.jamda.2006.09.005. J Am Med Dir Assoc. 2006. PMID: 17098634 Review.
Cited by
-
Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation.Int J Nephrol. 2011;2011:297070. doi: 10.4061/2011/297070. Epub 2011 Aug 9. Int J Nephrol. 2011. PMID: 21860794 Free PMC article.
-
Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.Perit Dial Int. 2014 Nov-Dec;34(7):706-13. doi: 10.3747/pdi.2012.00004. Epub 2014 Mar 1. Perit Dial Int. 2014. PMID: 24584618 Free PMC article.
-
Kidney function and the risk of cardiovascular events in HIV-1-infected patients.AIDS. 2010 Jan 28;24(3):387-94. doi: 10.1097/QAD.0b013e3283359253. AIDS. 2010. PMID: 20019575 Free PMC article.
-
Cadmium regulates von Willebrand factor and occludin expression in glomerular endothelial cells of mice in a TNF-α-dependent manner.Ren Fail. 2019 Nov;41(1):354-362. doi: 10.1080/0886022X.2019.1604383. Ren Fail. 2019. PMID: 31057027 Free PMC article.
-
A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease.Ther Adv Drug Saf. 2017 Oct;8(10):305-318. doi: 10.1177/2042098617716819. Epub 2017 Jul 12. Ther Adv Drug Saf. 2017. PMID: 29593859 Free PMC article.
References
-
- Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97. - PubMed
-
- Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109:IV6–IV19. - PubMed
-
- Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–1016. - PubMed
-
- Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis. 2005;45:39–47. - PubMed
-
- Hjerkinn EM, Seljeflot I, Sandvik L, Hjermann I, Arnesen H. Markers of endothelial cell activation in elderly men at high risk for coronary heart disease. Scand J Clin Lab Invest. 2005;65:201–209. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous